文献速递乳腺技术与安全US

全氟丁烷超声造影血管后期用于早期乳腺癌腋窝淋巴结状态术前评估

Post-vascular phase of contrast-enhanced ultrasound with perfluorobutane for preoperative evaluation of axillary lymph node status in early-stage breast cancer.
PubMed 文献 · Radiol Med · 2025-04-07

前瞻性研究纳入146例早期浸润性乳腺癌伴不可触及腋窝淋巴结患者,评估全氟丁烷超声造影血管后期成像诊断腋窝淋巴结转移和预测转移负荷的可行性。血管后期「血管后期缺损」诊断阳性腋窝淋巴结的AUC为0.92,敏感度99%,阴性预测值98%,优于常规超声和血管期成像。在89例手术队列中,血管后期缺损淋巴结数目对无病腋窝预测AUC为0.90。

要点

  • 血管后期「血管后期缺损」诊断腋窝淋巴结转移AUC 0.92,敏感度99%,阴性预测值98%。
  • 血管后期成像诊断效能优于常规超声(AUC 0.77)和血管期成像(AUC 0.85)。
  • 血管后期缺损淋巴结数目可预测转移负荷,无病腋窝AUC 0.90。

核心结论

  • 全氟丁烷超声造影血管后期成像在早期浸润性乳腺癌患者术前评估腋窝淋巴结状态方面表现出良好效能。

研究设计与样本

  • 前瞻性研究,2022年11月至2023年6月纳入146例早期浸润性乳腺癌伴不可触及腋窝淋巴结的女性患者,全体队列均行常规超声和全氟丁烷超声造影检查,随后根据超声造影结果行超声引导下空心针穿刺活检;手术队列89例未接受新辅助化疗直接行腋窝手术。

关键影像表现/征象

  • 血管后期成像的主要特征为「血管后期缺损」,用于诊断阳性腋窝淋巴结转移。
  • 常规超声、血管期成像和血管后期成像的主要特征根据阳性与阴性腋窝淋巴结转移组间比较选择。

诊断标准与关键数值

  • 血管后期缺损诊断阳性腋窝淋巴结转移的AUC为0.92(95%CI 0.86, 0.97),敏感度99%(95%CI 93%, 100%),阴性预测值98%(95%CI 90%, 100%)。
  • 常规超声诊断阳性腋窝淋巴结转移的AUC为0.77(95%CI 0.69, 0.85),血管后期成像优于常规超声(P < 0.001)。
  • 血管期成像诊断阳性腋窝淋巴结转移的AUC为0.85(95%CI 0.78, 0.91),血管后期成像优于血管期成像(P < 0.001)。
  • 手术队列89例中,血管后期缺损淋巴结数目预测无病腋窝的AUC为0.90(95%CI 0.82, 0.97)。
  • 手术队列89例中,血管后期缺损淋巴结数目区分低转移负荷与重转移负荷的AUC为0.75(95%CI 0.60, 0.89)。

临床应用与阅片要点

  • 血管后期成像可作为术前评估早期浸润性乳腺癌腋窝淋巴结状态的影像学方法,血管后期缺损提示阳性腋窝淋巴结转移。
  • 血管后期缺损淋巴结数目有助于预测腋窝转移负荷,包括无病腋窝和低与重转移负荷的区分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the feasibility of post-vascular phase imaging on contrast-enhanced ultrasound (CEUS) with perfluorobutane for diagnosing axillary lymph node metastasis (ALNM) and prediction of metastatic burden in early-stage breast cancer.

MATERIAL AND METHODS: The prospective study enrolled patients with early-stage invasive breast cancer and non-palpable axillary lymph node (ALN) from November 2022 to June 2023. All participants of the entire cohort were scheduled for both conventional ultrasound (US) and CEUS with perfluorobutane examination immediately followed by US-guided core-needle biopsy basing on the guidance of CEUS result. The main features of US, vascular phase imaging, and post-vascular phase imaging were selected according to comparison between positive and negative ALNM using the Chi-square or Fisher exact test, of which diagnostic performance of different combinations on ALNM was calculated and compared for determining optimal diagnostic criteria. As for burden analysis, the predictive power of number of lymph nodes with post-vascular defect for metastatic burden was also estimated among surgery cohort who underwent axillary surgery without neoadjuvant chemotherapy.

RESULTS: A total of 146 female patients (median age, 51 [42-58] years) with 146 target ALNs (median size, 16 [13-21] mm; 82 positive ALNM and 64 negative ALNM) were enrolled in the entire cohort. The post-vascular phase finding "post-vascular defect" had an AUC of 0.92 (95% CI 0.86, 0.97) and sensitivity of 99% (95% CI 93%, 100%) with a negative predictive value of 98% (95% CI 90%, 100%) for the diagnosis of positive ALNM. Overall, the post-vascular phase finding performed better than that of US (AUC, 0.77, 95% CI 0.69, 0.85, P < 0.001) and vascular phase findings (AUC, 0.85, 95% CI 0.78, 0.91, P < 0.001). As for burden analysis among surgery cohort with 89 patients, the number of lymph nodes with post-vascular defect was highly predictive of metastatic burden, with AUC of 0.90 (95% CI 0.82, 0.97) for predicting disease-free axilla and AUC of 0.75 (95% CI 0.60, 0.89) for discriminating between low and heavy metastatic burden.

CONCLUSION: Post-vascular phase imaging on CEUS with perfluorobutane demonstrated good performance for preoperatively assessing the ALN status in patients with early-stage invasive breast cancer. Chinese Clinical Trial Registry No. ChiCTR2400080297.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Hu Y, Li Q, Huang Y, et al. Post-vascular phase of contrast-enhanced ultrasound with perfluorobutane for preoperative evaluation of axillary lymph node status in early-stage breast cancer. Radiol Med. 2025. PMID: 40192923. doi:10.1007/s11547-025-01980-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。